8/9 responders (this is not necessarily accurate as some...

8/9 responders (this is not necessarily accurate as some previous patients may have converted to SDs?).

This is amazing in all comers advanced solid tumors. Let's not forget that its cancer they are trying to treat, not a specific mutation.

I wonder if mgmt took a delayed and quiet approach to ann this because they are (rightly) worried the asx market would think it is bad because no further CRs? They perhaps delayed the data cut in the hope of getting one and didn't, yet, as well?

Anyway, 50% have responded overall so far, but 8 more from 9 patients added since last update sounds a lot better. This makes laymans sense as well due to high doses and more time on treatment for some patients.

If I've missed something here please let me know?

Come on leslie, get someone to spin this analysis as the bees knees. I will for the right price.

GLTA.